Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Post by Chyler1on Dec 31, 2020 10:10pm
326 Views
Post# 32206498

Reality folks

Reality folks

No sales contracts and no mention of any 
company will only update on sales every quarter meaning next update March 31
Roche and Abbott have already squeezed out all other antigen tests in Europe of which there are many all with Ce mark 
price Roche and Abbott are selling for in Europe is $6 USD
Why would European customers be interested in Sona when there are so many other tests in the market including Roche and Abbott who have fda and hc approvals and have already signed big contracts ?
HC said they wanted more data before they would consider test 
FDA said they weren't interested in approving their test as EUA 
havent started clinical trials yet for  resubmission to HC or fda for nasalpharyngal test

Haven't completed prototype yet for saliva test 
may least one lawsuit has been filed against the company 


tell me again why anyone other than a short would be interested in this stock right now with a $200m+ market cap ?  Just asking 


 

 

<< Previous
Bullboard Posts
Next >>